Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: A systematic review and meta-analysis of real-world observational

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Heng, Daniel Y ^a   Signorovitch, James ^b   Swallow, Elyse ^b   Li, Nanxin ^b   Zhong, Yichen ^b   Qin, Paige ^b   Zhuo, Daisy Y ^b   Wang, Xufang ^c   Park, Jinhee ^c   Stergiopoulos, Sotirios ^c   Kollmannsberger, Christian ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b ANALYSIS GROUP   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN;

ARTICLE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; GENETIC HETEROGENEITY; HUMAN; KIDNEY CARCINOMA; META ANALYSIS; MULTICENTER STUDY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEQUENTIAL ANALYSIS; SYSTEMATIC REVIEW; CARCINOMA, RENAL CELL; COMPARATIVE STUDY; KIDNEY NEOPLASMS; METASTASIS; PATHOLOGY; SURVIVAL ANALYSIS;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; SURVIVAL ANALYSIS;

EID: 84956612027     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114394     Document Type: Article

References (29)

1. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C (2008) Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 34: 193-205.
2. Cancer Research UK (2013) Kidney cancer incidence statistics.
3. Lam JS, Leppert JT, Belldegrun AS, Figlin RA (2005) Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 23: 202-212.
4. NCCN Guidelines (2014) NCCN Clinical Practice Guidelines in Oncology, Kidney Cancer (version 2.2014).
5. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, et al. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456.
6. Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, et al. (2014) Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol 32: 760-767.
7. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, et al. (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378: 1931-1939.
8. Wong MK, Yang H, Signorovitch JE, Wang X, Liu Z, et al. (2013) Comparative Outcomes of Everolimus, Temsirolimus and Sorafenib as Second Targeted Therapies for Metastatic Renal Cell Carcinoma: A U.S. Medical Record Review. Curr Med Res Opin.
9. Iacovelli R, Carteni G, Sternberg CN, Milella M, Santoni M, et al. (2013) Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. Eur J Cancer.
10. Chen CC, Hess GP, Liu Z, Gesme DH, Agarwala SS, et al. (2012) Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma. Clin Genitourin Cancer 10: 256-261.
11. Egger M, Schneider M, Davey Smith G (1998) Spurious precision? Meta-analysis of observational studies. BMJ 316: 140-144.
12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339: b2700.
13. Wells GA, Shea B, O'Connell D, Peterson J, Welch W, et al. (2011) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis.
14. Lash TL, Cole SR (2009) Immortal person-time in studies of cancer outcomes. J Clin Oncol 27: e55-56.
15. Koepsell TD, Weiss NS (2003) Epidemiologic Methods: Studying the Occurrence of Illness: Oxford University Press.
16. Elwood M (2007) Critical Appraisal of Epidemiological Studies and Clinical Trials: Oxford University Press.
17. Meinert CL (2012) Clinical Trials: Design, Conduct and Analysis: Oxford University Press.
18. R Core Team (2012) R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
19. Busch J, Seidel C, Erber B, Issever AS, Hinz S, et al. (2013) Retrospective comparison of triplesequence therapies in metastatic renal cell carcinoma. Eur Urol 64: 62-70.
20. Busch J, Seidel C, Kempkensteffen C, Johannsen M, Wolff I, et al. (2011) Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur Urol 60: 1163-1170.
21. Park K, Lee JL, Park I, Park S, Ahn Y, et al. (2012) Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI. Med Oncol 29: 3291-3297.
22. Heng DYC, Lee J-L, Harshman LC, Bjarnason GA, Razak AR, et al. (2012) A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts 30: 387.
23. Gore ME, Hutson TE, Lin X, Korytowsky B, Lechuga MJ, et al. (2013) Treatment sequencing following first-line sunitinib in patients (pts) with advanced renal cell carcinoma (RCC). ESMO Meeting Abstract.
24. Ruiz AL, Bolos MV, Viqueira A, Esteban E (2013) Outcome of metastatic renal cell carcinoma (mRCC) patients in the era of new targeted therapies. ESMO Meeting Abstract.
25. Elaidi RT, Harbaoui AH, Beuselinck B, Eymard JC, Bamias A, et al. (2013) What is the best treatment option for second-line in long-responders to the first line TKI in metastatic renal cell carcinoma (mRCC) patients (pts): TKI-TKI or TKI-mTORi? Final results of a European retrospective study. ESMO Meeting Abstract.
26. Signorovitch JE, Vogelzang NJ, Pal SK, Lin PL, George DJ, et al. (2013) Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: Analysis of two practice-based chart reviews. ASCO Meeting Abstracts 31: e15504.
27. Harrison MR, George DJ, Walker MS, Hudson LL, Chen C, et al. (2012) Outcomes of ''real world'' treatment for metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts 30: 406.
28. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289-296.
29. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, et al. (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factortargeted agents: results from a large, multicenter study. J Clin Oncol 27: 5794-5799.